Refine by
Cell Therapeutic Articles & Analysis
135 news found
A promising approach for overcoming these problems to deliver drugs is the receptor-mediated transport (RMT) system, which employs vesicular trafficking to carry ligands across the endothelial cells of the BBB. Ace Therapeutics’ BBBporter™ platform-RMT-based brain drug delivery system-is committed to facilitating the transport of biologics across the ...
Creative BioMart, a biotechnology company specializing in cell line development and protein production, has recently upgraded its GMP stable cell line development platform. This platform provides biopharmaceutical companies with a structured and regulatory-compliant approach to develop stable cell lines for therapeutic proteins, ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Its end-to-end rare disease therapy development solutions cover a full package of therapeutic development services, which include small molecule, cell therapy, gene therapy, therapeutic antibody, therapeutic peptide, and therapeutic protein. ...
They are essential for the efficient transportation of mRNA to target cells, ensuring that therapeutic mRNA is delivered to the cytoplasm, where it can effectively produce the target protein. ...
However, a recent study by Milman-Krentsis (2024) offers a beacon of hope, demonstrating the potential of lung cell transplantation as a therapeutic intervention for lung fibrosis. Utilizing two distinct mouse models—one treated with bleomycin and another genetically modified to lack telomeric repeat-binding factor 1 (TRF1) in alveolar type 2 (AT2) ...
These hydrogels are pivotal in medical devices, regenerative medicine, drug delivery systems, 3D cell culture, and wound healing." Diverse Product Offering: Biopharma PEG’s multi-arm PEG products are available with various branching structures and functional groups to meet the specific needs of researchers and developers in the medical and bioorganic fields. ...
In this free webinar, learn about the challenges in maintaining reliability, reproducibility and consistency in induced pluripotent stem cell (iPSC) cultures. Attendees will be introduced to a novel cell line restoration method supported by high-throughput single-cell cloning technologies. The featured speakers will explore the different types of ...
In turn, this empowers researchers to gain a deeper insight into the role of these markers in diverse cell types and biological processes. Why opt for CD Genomics' 5mC/5hmC sequencing service? ...
Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. The Registration Statement contains a preliminary proxy ...
With cellvie, Alex is particularly excited about the chance to contribute to what may emerge as a new treatment modality: the therapeutic use of mitochondria. Alex's presentation at the award ceremony can be watched here: About cellvie AG Started in the US and headquartered in Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the ...
About cellvie Founded in the US and headquartered in Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. ...
She added, “As medicine moves towards personalized care, more precise cell recovery is required for research and pharmaceutical development, especially in the new fields of cell therapeutics and genomics. To address this challenge, we have brought to market our CytoR1 Platform - a label-free, fully-integrated product system for ...
(NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on MHC-like ...
It affects the drug's biological activity, serum half-life, stability, and immunogenicity, which alters how the drug interacts with the patient's cells. This is a crucial quality attribute of therapeutic protein drugs. ...
Rejuvenation therapies aim to reverse or repair age-related cellular changes such as molecular waste, calcification, tissue stiffening, loss of stem cell function, genetic alterations, and impaired energy production. ...
This program is an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). ...
Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. ...
It includes multiple Human leukocyte antigen (HLA)-specific immunotherapy cell lines that will be administered to patients based on each patient’s HLA type. ...